Optinose (OPTN): מחיר למכירות
The price-to-sales ratio for OptiNose, Inc. (OPTN) highlights margin risks stemming from generic competition and marketing expenses, while 1.20 reflects the latest value of this metric. OptiNose, Inc. (OPTN) generates revenue through the sale of patented systems for nasopharyngeal therapy. Operations are strictly regulated by FDA standards, which limits the environmental footprint solely to the disposal of biomaterials.
פילוחי מדדים ואנליטיקה של חברת Optinose (OPTN)
The P/S ratio determines the market value of a business relative to its annual sales volume, measuring the premium investors are willing to pay per unit of revenue. The capitalization-to-revenue trend reflects the efficiency of OptiNose, Inc. (OPTN) asset monetization amid aggressive marketing and generic pressure, where high costs to capture market share in nasal sprays may temporarily distort the company's fundamental valuation.
